S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Atara Biotherapeutics (ATRA) Stock Forecast & Price Target

$0.69
-0.02 (-2.81%)
(As of 04/18/2024 ET)

Atara Biotherapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 3 Analyst Ratings

Analysts' Consensus Price Target

$28.00
3,948.00% Upside
High Forecast$28.00
Average Forecast$28.00
Low Forecast$28.00
TypeCurrent Forecast
4/19/23 to 4/18/24
1 Month Ago
3/20/23 to 3/19/24
3 Months Ago
1/19/23 to 1/19/24
1 Year Ago
4/19/22 to 4/19/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
1 Buy rating(s)
3 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$28.00$28.00$28.00$19.25
Predicted Upside3,948.00% Upside1,617.79% Upside554.59% Upside237.13% Upside
Get Atara Biotherapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.

ATRA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ATRA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Atara Biotherapeutics Stock vs. The Competition

TypeAtara BiotherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.68
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside3,726.70% Upside923.57% Upside11.58% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/9/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ In-Line
11/9/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Burns
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
11/9/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:14 PM ET.

ATRA Price Target - Frequently Asked Questions

What is Atara Biotherapeutics's consensus rating and price target?

According to the issued ratings of 3 analysts in the last year, the consensus rating for Atara Biotherapeutics stock is Hold based on the current 3 hold ratings for ATRA. The average twelve-month price prediction for Atara Biotherapeutics is $28.00 with a high price target of $28.00 and a low price target of $28.00. Learn more on ATRA's analyst rating history.

Do Wall Street analysts like Atara Biotherapeutics more than its competitors?

Analysts like Atara Biotherapeutics less than other Medical companies. The consensus rating for Atara Biotherapeutics is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how ATRA compares to other companies.

Does Atara Biotherapeutics's stock price have much upside?

According to analysts, Atara Biotherapeutics's stock has a predicted upside of 1,617.79% based on their 12-month stock forecasts.


Stock Ratings Reports and Tools

This page (NASDAQ:ATRA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners